Novavax, Inc. (NVAX)
After hours:
| Previous close | 6.59 |
| Open | 6.63 |
| Bid | 6.97 x 2200 |
| Ask | 6.98 x 2200 |
| Day's range | 6.56 - 7.13 |
| 52-week range | 5.61 - 77.65 |
| Volume | |
| Avg. volume | 6,521,327 |
| Market cap | 589.078M |
| Beta (5Y monthly) | 1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Novavax (NVAX) closed at $6.59, marking a -1.05% move from the previous day.
- Zacks
Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
1 Growth Stock With 741% Upside, According to Wall Street
Shares of biotech Novavax (NASDAQ: NVAX) have plunged 91% in the past year as the company has struggled to make its mark in the coronavirus vaccine market. Novavax's lack of success in this space is even more troubling, considering global COVID-19 vaccine sales will drop substantially starting this year, so even the leaders in the field have struggled of late. While it seems highly unlikely that Novavax will soar by that much anytime soon, perhaps the broader question is whether there's a substantial upside ahead for the company.
